云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀-B

国庆日翌日休市 09-29 16:08:22

25.000

+0.550

+2.25%

最高25.400	最低24.150	成交量68.63万
今开24.400	昨收24.450	日振幅5.11%
总市值79.18亿	流通市值79.18亿	总股本3.17亿
成交额1,708万	换手率0.22%	流通股本3.17亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀-B","latestPrice":25,"timestamp":1695974902029,"preClose":24.45,"halted":0,"volume":686259,"delay":0,"floatShares":316726026,"shares":316726026,"eps":-0.89123976,"marketStatus":"国庆日翌日休市","marketStatusCode":7,"change":0.55,"latestTime":"09-29 16:08:22","open":24.4,"high":25.4,"low":24.15,"amount":17077353,"amplitude":0.051125,"askPrice":25.1,"askSize":11000,"bidPrice":25,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.010174704721325856,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1696296600000},"adr":0,"listingDate":1602172800000,"adjPreClose":24.45,"volumeRatio":0.07965777911346539,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"2371537092","title":"云顶新耀依拉环素在中国台湾获批上市，用于成人复杂性腹腔内感染","url":"https://stock-news.laohu8.com/highlight/detail?id=2371537092","media":"新京报","top":-1,"share":"https://www.laohu8.com/m/news/2371537092?lang=zh_cn&edition=full","pubTime":"2023-09-30 09:41","pubTimestamp":1696038092,"startTime":"0","endTime":"0","summary":"新京报讯 9月28日，云顶新耀宣布，创新型强效抗菌药物依拉环素获中国台湾地区药政部门批准上市，用于治疗成人复杂性腹腔内感染。复杂性腹腔内感染由不同病原体引起，包括革兰阴性菌、革兰阳性菌和厌氧菌。依拉环素此前已在美国、欧盟、英国、新加坡、中国香港、中国大陆被批准用于治疗成人复杂性腹腔内感染。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023093009421582755927&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023093009421582755927&s=b","is_publish_highlight":false},{"id":"2370212617","title":"云顶新耀-B09月28日主力资金流出1074万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2370212617","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2370212617?lang=zh_cn&edition=full","pubTime":"2023-09-28 16:16","pubTimestamp":1695889018,"startTime":"0","endTime":"0","summary":"09月28日, 云顶新耀-B股价涨0.82%，报收24.45元，成交金额2.07亿元，换手率2.63%，振幅10.52%，量比1.10。云顶新耀-B今日主力资金净流出1074万元，连续7日净流出，上一交易日主力净流入2280万元。该股近5个交易日上涨34.51%，主力资金累计净流入2618万元；近20日主力资金累计净流入3159万元，其中净流入天数为10日。该股主力净额占比0.14%，港股市场排名2608/2622。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230928161733840bbe67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230928161733840bbe67&s=b","is_publish_highlight":false},{"id":"2370430187","title":"【港股通】云顶新耀-B(01952)再涨6.39% 近五个交易日涨超40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2370430187","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2370430187?lang=zh_cn&edition=full","pubTime":"2023-09-28 10:22","pubTimestamp":1695867766,"startTime":"0","endTime":"0","summary":"金吾财讯 | 云顶新耀-B 延续近日强势，开盘快速上扬，再涨6.39%，报25.8港元，成交额7492万港元。高盛将云顶新耀目标价由17.96港元上调至18.28港元，维持“中性”评级。预计zetomipzomib 将于2027年在中国推出，2032年或达风险调整后销售高峰的约5.5亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=7972b39a98f3a28cd07e2458dff8c2b4","is_publish_highlight":false},{"id":"2370437597","title":"云顶新耀-B现涨超6% 股价创今年2月份以来新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2370437597","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2370437597?lang=zh_cn&edition=full","pubTime":"2023-09-28 10:07","pubTimestamp":1695866849,"startTime":"0","endTime":"0","summary":"云顶新耀-B（01952）早盘曾涨近8%，高见26.20港元，创今年2月份以来新高，现涨6.39%，报25.80港元，成交额6977.590万港元。\n　　高盛早前将云顶新耀目标价由17.96港元上调至18.28港元，维持“中性”评级。预计zetomipzomib 将于2027年在中国推出，2032年或达风险调整后销售高峰的约5.5亿元。\n　　日前，公司宣布中国国家药品监督管理局药品审评中心拟将注射用头孢吡肟/他尼硼巴坦纳入优先审评品种。\n\n现在送您60元福利红包，直接提现不套路~~~快来参与活动吧！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-28/doc-imzpfksq8464852.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-28/doc-imzpfksq8464852.shtml","is_publish_highlight":false},{"id":"2370277748","title":"港股异动 | 云顶新耀-B(01952)续涨7% 依嘉®在中国台湾获批用于治疗成人复杂性腹腔内感染","url":"https://stock-news.laohu8.com/highlight/detail?id=2370277748","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2370277748?lang=zh_cn&edition=full","pubTime":"2023-09-28 09:51","pubTimestamp":1695865904,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B涨超7%，高见26.2港元创今年2月份以来新高。截至发稿，涨6.19%，报25.75港元，成交额5758.46万港元。消息面上，云顶新耀今日宣布中国台湾地区药政部门已批准创新型强效抗菌药物依嘉用于治疗成人复杂性腹腔内感染的新药上市许可申请。据悉，依嘉是全球首个氟环素类抗菌药物，用于治疗包括临床常见多重耐药菌所引起的感染，其于2023年3月获得中国国家药品监督管理局的批准。该产品在新加坡也已获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1001003.html","is_publish_highlight":false},{"id":"2370710016","title":"迈博药业-B盘中异动 早盘股价大跌5.05%报0.470港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2370710016","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2370710016?lang=zh_cn&edition=full","pubTime":"2023-09-28 09:40","pubTimestamp":1695865206,"startTime":"0","endTime":"0","summary":"2023年09月28日早盘09时40分，迈博药业-B股票出现波动，股价快速跳水5.05%。截至发稿，该股报0.470港元/股，成交量7.6万股，换手率0.00%，振幅5.05%。资金方面，该股资金流入2.475万港元，流出1.222万港元。迈博药业-B股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，北海康成-B、云顶新耀-B、中国抗体-B涨幅较大，振幅较大的相关个股有北海康成-B、华康生物医学、云顶新耀-B，振幅分别为19.85%、16.42%、8.25%。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202309280940068475ab80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202309280940068475ab80&s=b","is_publish_highlight":false},{"id":"2370711420","title":"云顶新耀宣布创新型强效抗菌药物依嘉®在中国台湾获批用于治疗成人复杂性腹腔内感染","url":"https://stock-news.laohu8.com/highlight/detail?id=2370711420","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2370711420?lang=zh_cn&edition=full","pubTime":"2023-09-28 07:30","pubTimestamp":1695857400,"startTime":"0","endTime":"0","summary":"上海2023年9月28日 /美通社/ --云顶新耀是一家专注于创新药和疫苗开发、制造及商业化的生物制药公司，今日宣布中国台湾地区药政部门已批准创新型强效抗菌药物依嘉用于治疗复杂性腹腔内感染的新药上市许可申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4221749_ZH21749_1","is_publish_highlight":false},{"id":"2370619756","title":"港股异动 | 云顶新耀-B续涨超6%逼近阶段高价 4日连涨达35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2370619756","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2370619756?lang=zh_cn&edition=full","pubTime":"2023-09-27 16:08","pubTimestamp":1695802109,"startTime":"0","endTime":"0","summary":"来源：格隆汇云顶新耀-B(1952.HK)再度拉升涨超6%，4日连涨高达35%，最高报24.65港元逼近阶段高价，总市值76.2亿港元。高盛将云顶新耀目标价由17.96港元上调至18.28港元，维持“中性”评级。预计zetomipzomib 将于2027年在中国推出，2032年或达风险调整后销售高峰的约5.5亿元。日前，公司宣布中国国家药品监督管理局药品审评中心拟将注射用头孢吡肟/他尼硼巴坦纳入优先审评品种。\n\n现在送您60元福利红包，直接提现不套路~~~快来参与活动吧！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-09-27/doc-imzpcwrh9187534.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-09-27/doc-imzpcwrh9187534.shtml","is_publish_highlight":false},{"id":"2370073531","title":"港股异动 | 云顶新耀-B(01952)再涨超6% zetomipzomib有望于2027年在中国推出","url":"https://stock-news.laohu8.com/highlight/detail?id=2370073531","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2370073531?lang=zh_cn&edition=full","pubTime":"2023-09-27 10:45","pubTimestamp":1695782758,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B再涨超6%，近六个交易日累涨近38%。消息面上，9月21日，云顶新耀宣布以700万美元的预付款以及最高为1.255亿美元的临床和商业里程碑付款获得Kezar旗下用于治疗活跃狼疮性肾炎的潜在“first-in-class”候选药物zetomipzomib在大中华区、韩国和部分东南亚国家进行临床开发和商业化权益。高盛发表报告，将云顶新耀目标价由17.96港元上调至18.28港元，维持“中性”评级。该行预计，zetomipzomib将于2027年在中国推出，2032年或达风险调整后销售高峰的约5.5亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1000361.html","is_publish_highlight":false},{"id":"2370733351","title":"股价3个交易日飙升25%！云顶新耀的前景如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2370733351","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2370733351?lang=zh_cn&edition=full","pubTime":"2023-09-27 10:19","pubTimestamp":1695781195,"startTime":"0","endTime":"0","summary":"9月26日，云顶新耀-B（01952.HK）再度上涨6.59%，至此在最近的3个交易日内该股已累涨24.86%，且上涨期间成交量亦有所放大。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202309_1/ce211eec-df2e-448e-a492-be7f2e7b762b.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202309_1/ce211eec-df2e-448e-a492-be7f2e7b762b.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/6513914bbde0b375aabeacec","is_publish_highlight":false},{"id":"2370226482","title":"云顶新耀-B09月26日获主力加仓1049万元 环比增加1262.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2370226482","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2370226482?lang=zh_cn&edition=full","pubTime":"2023-09-26 16:16","pubTimestamp":1695716201,"startTime":"0","endTime":"0","summary":"09月26日, 云顶新耀-B股价涨6.59%，报收22.65元，成交金额1.86亿元，换手率2.58%，振幅13.41%，量比1.41。云顶新耀-B今日主力资金净流入1049万元，连续5日净流入，上一交易日主力净流入77万元，今日环比增加1262.34%。该股近5个交易日上涨30.32%，主力资金累计净流入1895万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1806万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230926161722826afa36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230926161722826afa36&s=b","is_publish_highlight":false},{"id":"2370233246","title":"云顶新耀-B早盘股价持续升高 现涨逾10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2370233246","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2370233246?lang=zh_cn&edition=full","pubTime":"2023-09-26 11:49","pubTimestamp":1695700149,"startTime":"0","endTime":"0","summary":"云顶新耀-B（01952）早盘股价持续升高，上涨9.88%，现报23.35港元，成交额1.429亿港元。\n　　9月21日，云顶新耀宣布以700万美元的预付款以及最高为1.255亿美元的临床和商业里程碑付款获得Kezar旗下用于治疗活跃狼疮性肾炎（LN）的潜在“first-in-class”候选药物zetomipzomib在大中华区、韩国和部分东南亚国家进行临床开发和商业化权益。\n\n现在送您60元福利红包，直接提现不套路~~~快来参与活动吧！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-26/doc-imznzaui1376609.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-26/doc-imznzaui1376609.shtml","is_publish_highlight":false},{"id":"2370324555","title":"港股异动｜云顶新耀一度涨超11% 高盛上调目标价至18.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2370324555","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2370324555?lang=zh_cn&edition=full","pubTime":"2023-09-26 10:46","pubTimestamp":1695696409,"startTime":"0","endTime":"0","summary":"云顶新耀一度涨超11%，最高触及23.7港元，目前涨幅收窄至约8%。高盛发表报告，将云顶新耀目标价由17.96港元上调至18.28港元，维持“中性”评级。预计zetomipzomib 将于2027年在中国推出，2032年或达风险调整后销售高峰的约5.5亿元。此外，云顶新耀日前与生物制药公司Kezar订立合作及授权许可协议，获独家授权许可在大中华区、韩国及若干东南亚国家开发、生产及商业化Kezar的主要候选药物Zetomipzomib。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230926104803826a29eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230926104803826a29eb&s=b","is_publish_highlight":false},{"id":"2370243801","title":"港股异动 | 云顶新耀-B(01952)再涨超10% 公司引进狼疮性肾炎治疗产品 加码肾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2370243801","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2370243801?lang=zh_cn&edition=full","pubTime":"2023-09-26 10:32","pubTimestamp":1695695554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B(01952)再涨超10%，截至发稿，涨9.65%，报23.3港元，成交额8448.63万港元。消息面上，9月21日，云顶新耀宣布以700万美元的预付款以及最高为1.255亿美元的临床和商业里程碑付款获得Kezar旗下用于治疗活跃狼疮性肾炎（LN）的潜在“first-in-class”候选药物zetomipzomib在大中华区、韩国和部分东南亚国家进行临床开发和商业化权益。据悉，除了狼疮性肾炎之外，云顶新耀和Kezar还有机会在其他自身免疫性疾病如系统性红斑狼疮的临床试验和适应症方面进行合作，以继续开发zetomipzomib。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/999591.html","is_publish_highlight":false},{"id":"2370323349","title":"南向资金9月22日净买入云顶新耀-B101.80万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2370323349","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2370323349?lang=zh_cn&edition=full","pubTime":"2023-09-25 09:30","pubTimestamp":1695605458,"startTime":"0","endTime":"0","summary":"9月22日, 南向资金增持云顶新耀-B101.80万股，连续3日增持。截止当日收盘，港股通共持有云顶新耀-B8487.20万股，占流通股26.79%。云顶新耀-B近5个交易日上涨19.87%，港股通累计增持148.95万股；近20个交易日上涨24.26%，港股通累计增持34.55万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202309250941548266ef1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202309250941548266ef1e&s=b","is_publish_highlight":false},{"id":"2369461454","title":"加码肾病领域 云顶新耀超1亿美元引进狼疮性肾炎治疗产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2369461454","media":"蓝鲸财经","top":-1,"share":"https://www.laohu8.com/m/news/2369461454?lang=zh_cn&edition=full","pubTime":"2023-09-22 16:52","pubTimestamp":1695372764,"startTime":"0","endTime":"0","summary":"继全球唯一IgA肾病的对因治疗药物耐赋康&reg;新药上市申请（NDA）获得中国国家药品监督管理局的优先审评后，云顶新耀（HKEX1952.HK）继续加码肾病领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202309222855942659.html","is_publish_highlight":false},{"id":"2369946940","title":"港股收盘(09.22) | 恒指收涨2.28%重返万八关口 科网、医药、大金融股等强势领跑","url":"https://stock-news.laohu8.com/highlight/detail?id=2369946940","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2369946940?lang=zh_cn&edition=full","pubTime":"2023-09-22 16:33","pubTimestamp":1695371588,"startTime":"0","endTime":"0","summary":"截止收盘，恒生指数涨2.28%或402.04点，报18057.45点，本周累跌0.69%，全日成交额1018.47亿港元；恒生国企指数涨2.68%，报6262.61点；恒生科技指数涨3.69%，报3991.33点。截至收盘，涨6.72%，报8.58港元，成交额4.68亿港元，贡献恒指1.9点。隔夜美元指数创6个月新高，10年期美债收益率一度触及4.4881%，2年期国债收益率最高上涨至5.1202%，均创16年来新高。截至收盘，该股涨8.68%，报1","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/998479.html","is_publish_highlight":false},{"id":"2369346615","title":"云顶新耀-B09月22日获主力加仓283万元 环比增加6975.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2369346615","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2369346615?lang=zh_cn&edition=full","pubTime":"2023-09-22 16:15","pubTimestamp":1695370508,"startTime":"0","endTime":"0","summary":"09月22日, 云顶新耀-B股价涨16.04%，报收21.05元，成交金额2.98亿元，换手率4.58%，振幅20.84%，量比5.21。云顶新耀-B今日主力资金净流入283万元，连续3日净流入，上一交易日主力净流入4万元，今日环比增加6975.00%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为53.33%，平均涨幅为5.11%。该股近5个交易日上涨19.59%，主力资金累计净流入593万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入897万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023092216151983faacdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023092216151983faacdb&s=b","is_publish_highlight":false},{"id":"2369568314","title":"高盛：维持云顶新耀-B(01952)“中性”评级 目标价升至18.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2369568314","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2369568314?lang=zh_cn&edition=full","pubTime":"2023-09-22 11:38","pubTimestamp":1695353931,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研究报告称，将云顶新耀-B目标价由17.96港元上调2%至18.28港元，但扩大每股亏损预测，以反映研发开支增加、美元兑人民币汇率更新、估值中新增zetomipzomib计算，以及将mRNA疫苗从估值中移除，维持“中性”评级。另调整公司2023-2024年每股亏损预测，分别由3.23/2.69元人民币扩大至3.3/2.77元人民币，同时估计zetomipzomib将于2027年在中国推出，2032年或达风险调整后销售高峰的约5.5亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/998354.html","is_publish_highlight":false},{"id":"2369585384","title":"云顶新耀-B早盘股价持续上扬 现涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2369585384","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2369585384?lang=zh_cn&edition=full","pubTime":"2023-09-22 10:23","pubTimestamp":1695349387,"startTime":"0","endTime":"0","summary":"云顶新耀-B（01952）早盘股价持续上扬，大涨8.49%，现报19.68港元，成交额4266.546万港元。\n　　云顶新耀发布公告，与Kezar订立合作及授权许可协议。据此，Kezar授予公司独家授权许可，在大中华区、韩国及若干东南亚国家开发、生产及商业化Kezar的主要候选药物zetomipzomib，其为一种用于治疗包括狼疮性肾炎在内的一系列自身免疫性疾病的新同类首创选择性免疫蛋白酶体抑制剂。\n\n现在送您60元福利红包，直接提现不套路~~~快来参与活动吧！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-22/doc-imznpwaq8122176.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-22/doc-imznpwaq8122176.shtml","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1876},{"period":"1month","weight":0.3721},{"period":"3month","weight":0.0504},{"period":"6month","weight":0.6192},{"period":"1year","weight":2.3738},{"period":"ytd","weight":0.4384}],"websiteUrl":"http://www.everestmedicines.com","compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0364},{"period":"3month","weight":-0.0585},{"period":"6month","weight":-0.127},{"period":"1year","weight":0.0375},{"period":"ytd","weight":-0.0997}],"name":"云顶新耀-B","description":"云顶新耀有限公司是一家主要从事疗法的特许、临床开发及商业化业务，以解决尚未满足的医疗需求。该公司一直专注于创新候选药物的研发。该公司已开发极具前景的临床阶段候选药物产品组合，覆盖肿瘤、免疫学、心肾疾病及感染性疾病。该公司主要在大中华及亚太区其他新兴市场提供产品与服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.141891},{"month":2,"riseRate":0,"avgChangeRate":-0.145578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.032283},{"month":4,"riseRate":0,"avgChangeRate":-0.145301},{"month":5,"riseRate":0.666667,"avgChangeRate":0.018155},{"month":6,"riseRate":1,"avgChangeRate":0.412865},{"month":7,"riseRate":0,"avgChangeRate":-0.200039},{"month":8,"riseRate":0,"avgChangeRate":-0.206077},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011102},{"month":10,"riseRate":0,"avgChangeRate":-0.131191},{"month":11,"riseRate":0.666667,"avgChangeRate":0.243306},{"month":12,"riseRate":0.666667,"avgChangeRate":0.191127}],"exchange":"SEHK","nameEN":"EVEREST MED - B","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.17.2","shortVersion":"4.17.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀-B,01952,云顶新耀-B股票,云顶新耀-B股票老虎,云顶新耀-B股票老虎国际,云顶新耀-B行情,云顶新耀-B股票行情,云顶新耀-B股价,云顶新耀-B股市,云顶新耀-B股票价格,云顶新耀-B股票交易,云顶新耀-B股票购买,云顶新耀-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}